These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 7606729

  • 21. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
    Sabnis G, Goloubeva O, Jelovac D, Schayowitz A, Brodie A.
    Clin Cancer Res; 2007 May 01; 13(9):2751-7. PubMed ID: 17473209
    [Abstract] [Full Text] [Related]

  • 22. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice.
    Satyaswaroop PG, Zaino RJ, Mortel R.
    Cancer Res; 1984 Sep 01; 44(9):4006-10. PubMed ID: 6744316
    [Abstract] [Full Text] [Related]

  • 23. Aromatase inhibitors: rationale for use following antiestrogen therapy.
    Yue W, Santen RJ.
    Semin Oncol; 1996 Aug 01; 23(4 Suppl 9):21-7. PubMed ID: 8824461
    [Abstract] [Full Text] [Related]

  • 24. Antiproliferative effect of the new aromatase inhibitor fadrozole on pre- and postmenopausal models of rat mammary tumor.
    Tanaka M, Yano S, Hasegawa Y, Nakao K.
    Arzneimittelforschung; 1994 Jun 01; 44(6):774-8. PubMed ID: 8053980
    [Abstract] [Full Text] [Related]

  • 25. Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator.
    McDougal A, Wormke M, Calvin J, Safe S.
    Cancer Res; 2001 May 15; 61(10):3902-7. PubMed ID: 11358803
    [Abstract] [Full Text] [Related]

  • 26. A novel in vitro and in vivo breast cancer model for testing inhibitors of estrogen biosynthesis and its action using mammary tumor cells with an activated int-5/aromatase gene.
    Tekmal RR, Durgam VR.
    Cancer Lett; 1997 Sep 16; 118(1):21-8. PubMed ID: 9310256
    [Abstract] [Full Text] [Related]

  • 27. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
    Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM.
    Cancer Res; 2005 Jun 15; 65(12):5439-44. PubMed ID: 15958593
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
    Sonne-Hansen K, Lykkesfeldt AE.
    J Steroid Biochem Mol Biol; 2005 Jan 15; 93(1):25-34. PubMed ID: 15748829
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The effects of aromatase inhibitors and antiestrogens in the nude mouse model.
    Lu Q, Yue W, Wang J, Liu Y, Long B, Brodie A.
    Breast Cancer Res Treat; 1998 Jul 15; 50(1):63-71. PubMed ID: 9802621
    [Abstract] [Full Text] [Related]

  • 32. Antitumor effects of SEF19, a new nonsteroidal aromatase inhibitor, on 7,12-dimethylbenz[a]anthracene-induced mammary tumors in rats.
    Iino Y, Karakida T, Sugamata N, Andoh T, Takei H, Takahashi M, Yaguchi S, Matsuno T, Takehara M, Sakato M, Kawashima S, Morishita Y.
    Anticancer Res; 1998 Jul 15; 18(1A):171-6. PubMed ID: 9568073
    [Abstract] [Full Text] [Related]

  • 33. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice.
    Schafer JM, Lee ES, O'Regan RM, Yao K, Jordan VC.
    Clin Cancer Res; 2000 Nov 15; 6(11):4373-80. PubMed ID: 11106256
    [Abstract] [Full Text] [Related]

  • 34. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
    Belosay A, Brodie AM, Njar VC.
    Cancer Res; 2006 Dec 01; 66(23):11485-93. PubMed ID: 17145897
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Therapeutic observations in MCF-7 aromatase xenografts.
    Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S, Goloubeva O.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 2):884s-8s. PubMed ID: 15701882
    [Abstract] [Full Text] [Related]

  • 37. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo.
    Ye JJ, Liang SJ, Guo N, Li SL, Wu AM, Giannini S, Sachdev D, Yee D, Brünner N, Ikle D, Fujita-Yamaguchi Y.
    Horm Metab Res; 2003 Jan 15; 35(11-12):836-42. PubMed ID: 14710366
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. A spontaneous estrogen dependent, tamoxifen sensitive mouse mammary tumor: a new model system to study hormone-responsiveness in immune competent mice.
    Simian M, Manzur T, Rodriguez V, de Kier Joffé EB, Klein S.
    Breast Cancer Res Treat; 2009 Jan 15; 113(1):1-8. PubMed ID: 18183485
    [Abstract] [Full Text] [Related]

  • 40. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens.
    Brodie AH, Jelovac D, Long B.
    J Steroid Biochem Mol Biol; 2003 Sep 15; 86(3-5):283-8. PubMed ID: 14623522
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.